Physician profile
Sidney B Smith
NPI 1326139080
$12,577.72
in general payments reported to CMS, 2019-2025
32 companies · $2,298 in 2025
The $2,298 reported for 2025 was more than what 79% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,287 · 2020: $1,196 · 2021: $1,543 · 2022: $1,495 · 2023: $1,945 · 2024: $1,813 · 2025: $2,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,632 · Education: $424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,632.25 |
| Education | $423.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,124.71 | 2019-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $1,904.23 | 2019-2025 | Skyrizi, Botox, Rinvoq |
| Merz North America, INC. | $1,692.03 | 2019-2025 | |
| Lilly USA, LLC | $712.93 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $701.31 | 2019-2025 | |
| Amgen INC. | $683.92 | 2019-2025 | Otezla |
| Galderma Laboratories, L.P. | $677.32 | 2019-2025 | Nemluvio |
| Ucb, INC. | $647.72 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $458.15 | 2020-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $407.87 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $392.70 | 2019-2022 | |
| Allergan, INC. | $375.84 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $308.17 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $289.03 | 2019-2025 | |
| Dermavant Sciences, INC. | $167.39 | 2023-2024 | Vtama |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $165.04 | 2024-2025 | Hadlima, Vtama |
| Celgene Corporation | $118.59 | 2019 | |
| Biofrontera INC. | $117.22 | 2019-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Biowound Solutions, INC. | $103.63 | 2025 | Bio-Connekt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.44 | 2025 | Spevigo |
| Leo Pharma INC. | $99.80 | 2021-2023 | Adbry |
| Arcutis Biotherapeutics, INC. | $82.38 | 2023-2025 | Zoryve |
| Incyte Corporation | $58.37 | 2023-2024 | Opzelura |
| Dusa Pharmaceuticals, INC. | $29.37 | 2019 | |
| Mimedx Group, INC. | $26.81 | 2024 | |
| Pfizer INC. | $24.74 | 2022 | |
| Almirall LLC | $21.39 | 2023 | Klisyri |
| Prugen, INC. Pharmaceuticals | $18.90 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.26 | 2020 | |
| Sandoz INC. | $17.94 | 2019 | |
| Fresenius Kabi USA, LLC | $17.67 | 2023 | Idacio |
| Taro Pharmaceuticals USA, INC. | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidney Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.